Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro

The recent research shows that the inhibition of the nuclear factor-κB (NF-κB) pathway is a promising therapeutic option for patients who progress after treatment with the novel mutant-selective EGFR-TKIs. For propose to find a nontoxic drug to reverse the acquired gefitinib resistance, we examined...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yong, Zang, Jialan, Cao, Haixia, Wu, Ying, Yan, Dali, Qin, Xiaobing, Zhou, Leilei, Fan, Fan, Ni, Jie, Xu, Xiaoyue, Sha, Huanhuan, Liu, Siwen, Yu, Shaorong, Wang, Zhuo, Ma, Rong, Wu, Jianzhong, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362524/
https://www.ncbi.nlm.nih.gov/pubmed/28178657
http://dx.doi.org/10.18632/oncotarget.15007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362524/
https://www.ncbi.nlm.nih.gov/pubmed/28178657
http://dx.doi.org/10.18632/oncotarget.15007

Ejemplares similares